Table 2. Mean LTG daily dose and concentrations in the different concomitant AEDs groups and their statistical significance versus patients in group A.
| Number of samples | LTG dose (mg/day) |
Significance (P) |
LTG concentration Mean±SD (μg/mL) |
Significance (P) |
|
|---|---|---|---|---|---|
| Group A: LTG monotherapy | 71 | 156.93±52.99 | -- | 3.97±2.06 | -- |
| Group B: LTG+AEDs with inducer | 39 | 168.60±40.84 | 1.00 | 2.75±1.93 | 0.04 |
| Group C: LTG+VPA | 68 | 156.62±59.32 | 1.00 | 7.70±4.22 | 0.00 |
| Group D: LTG+AEDs with non-inducer | 11 | 165.90±39.20 | 1.00 | 4.43±1.42 | 0.99 |
| Group E: LTG+VPA+ AEDs with inducer | 15 | 158.30±32.27 | 1.00 | 5.81±3.71 | 0.72 |
| Group F: LTG+VPA+ AEDs with non-inducer | 22 | 148.00±63.31 | 1.00 | 8.66±4.50 | 0.00 |
LTG: Lamotrigine; VPA: Valproic acid
Inducer include: CBZ: Carbamazepine; OXC: Oxcarbazepine; TPM: Topiramate
non-inducer include: Levetiracetam; Clonazepam